The invitation mentioned that the study was funded by a drug company, which to Fugh-Berman had no clear link to the drug or herbal products. She asked for more information about the company, and heard nothing back until August 24, 2004 when she received a completed draft of the article with her name on the cover page. The marketing company requested that she review the article and return any comments or changes she wanted to make. She was also informed that the sponsoring company had a drug that would compete with warfarin, and wanted to prime the market for the arrival of their new drug. [14]